Xcelience eyes EU growth; DSM inks deal with Paranta;

> After opening a new plant in Florida, Xcelience is looking to boost its EU trial supply business. Article

> DSM Pharmaceutical has inked a deal with Paranta Biosciences for process development and cGMP manufacture of Follistatin, the company's lead recombinant human protein. News

> Althea Technologies has won a contract to manufacture a circumsporozoite protein for Pfenex's malaria vaccine. Story

> Penn Pharma recently completed a new solid oral dose facility, and the company says it's in talks with Big Pharma on potential partnerships. More

> AMRI has extended its extended its supply agreement with Shire ($SHPG) for another 5 years. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.